Stem Cell Therapy for COPD in Republic of Korea — Get 3 Top Clinic Matches with Costs

Stem cell therapy for COPD in South Korea is currently an experimental treatment regulated under the Advanced Regenerative Bio Act. While not a standard cure, specialized clinics like RE:YOUTH in Cheonan offer advanced arterial infusion techniques within a strictly monitored medical framework.

• Legal status: Regulated by the Ministry of Food and Drug Safety as high-risk therapy.
• Access pathway: Available through approved clinical research protocols or specialized regenerative medical centers.
• Cost range: Treatment typically costs between $9,000 and $20,000 for complex protocols.
• Delivery method: Specific facilities use direct arterial infusion to target lung tissue inflammation.
• Accreditation: Top clinics hold Korea Institute for Healthcare Accreditation (KOIHA) certification for safety.

Bookimed Expert Insight: While most clinics use intravenous drips, RE:YOUTH (YONSEI BH Arterial Stemcell Clinic) uses a rare arterial delivery method. They limit intake to 2 patients daily to maintain VIP standards. This focus on small patient volumes often results in more personalized care compared to larger research hospitals.

Patient Consensus: Patients emphasize that stem cells are not a guaranteed fix for damaged lung architecture. Verified research confirms that standard treatments like pulmonary rehab remain vital alongside these new regenerative options.

South Korea regulates stem cell therapy for COPD through a dual-track framework under the Ministry of Food and Drug Safety (MFDS) and the Ministry of Health and Welfare (MOHW). This system follows the Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products.

• Dual-track oversight: The MFDS regulates commercial drugs, while the MOHW oversees hospital-based clinical research.
• Risk classification: Cultured stem cells are high-risk (Class III or IV) and require strict institutional review.
• Institutional requirements: Treatments must occur in certified medical institutions like RE:YOUTH (YONSEI BH) in Cheonan.
• Compliance standards: Clinics must follow Good Manufacturing Practice (GMP) and national long-term patient follow-up rules.

Bookimed Expert Insight: While South Korea maintains strict oversight, specialized clinics like RE:YOUTH (YONSEI BH) differentiate themselves by limiting intake to 2 patients daily. This VIP-focused approach ensures adherence to KOIHA safety standards while offering unique technologies like direct arterial stem cell infusion, which is rare even in a highly regulated market.

Patient Consensus: Patients note that eligibility depends on a lack of other medical options rather than just payment. Experts advise verifying that therapy is part of an officially reviewed pathway rather than a general wellness service.

South Korean clinics and research centers primarily use Mesenchymal Stem Cells (MSCs) for COPD investigations. Researchers prioritize umbilical cord-derived cells for their rapid division and immunomodulatory effects. Clinical applications also include bone marrow and adipose-derived sources to reduce lung inflammation and stimulate tissue repair.

• Cell source: Umbilical cord-derived MSCs are the most common type in South Korean trials.
• Delivery methods: Techniques include direct arterial infusion, intravenous MSC infusion, or bronchoscopic delivery.
• Primary goal: MSCs aim to suppress airway inflammation rather than replace damaged lung structures.
• Clinical status: These therapies remain investigational and adjunct to standard inhaler regimens.
• Accreditation: Leading centers like RE:YOUTH maintain Korea Institute for Healthcare Accreditation (KOIHA) standards.

Bookimed Expert Insight: While most clinics globally use simple intravenous drips, specialized centers in South Korea like RE:YOUTH now use direct arterial infusion. This targeted method aims to deliver cells more efficiently to damaged tissues. The clinic also limits intake to two patients daily to prioritize safety during these experimental procedures.

Patient Consensus: Patients emphasize that these treatments should be viewed as experimental rather than a guaranteed cure for emphysema. Experts suggest confirming whether cells are your own or donor-derived before starting any protocol.

International patients seeking stem cell therapy for COPD in South Korea typically require a stay of 7 to 14 days. The process involves remote medical record screening, in-person diagnostic testing, and specialized cell administration like direct arterial infusion at KOIHA-accredited facilities.

• Remote evaluation: Specialists review pulmonary function tests and CT scans before patients book travel.
• Clinical screening: Arrive 1 to 3 days early for blood panels and lung assessments.
• Cell administration: Procedures like direct arterial infusion are often outpatient and take a few hours.
• Post-procedure monitoring: Patients stay 3 to 7 days locally to monitor respiratory function before flying.

Bookimed Expert Insight: While most clinics use intravenous drips, RE:YOUTH in Cheonan offers direct arterial infusion. This method delivers cells closer to lung tissue. This clinic limits intake to two patients daily. This ensures VIP-level attention and better monitoring for international travelers with respiratory needs.

Patient Consensus: Patients emphasize verifying if the treatment uses true stem cells rather than platelet-rich plasma. They recommend coordinating with a local pulmonologist to manage oxygen needs during the long flight home.